Pharming Group N.V.

PHAR48

$8.04arrow_drop_up1.25%$0.10

PHAR48

$8.04

arrow_drop_up1.25%$0.10

Performance History

There's no data available for key stats

There's no data available for ratios/profitability stats

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Pharming Group N.V. (PHAR)

Pharming Group N.V. (PHAR) is a leading biotechnology company specializing in the development of innovative protein replacement therapies. The company is focused on addressing unmet medical needs in the field of rare diseases and has a strong track record of success. With a market cap of over $1 billion, Pharming Group N.V. is well-positioned for growth and is an attractive investment opportunity. The company's stock price history shows a steady upward trend, indicating investor confidence in its potential. Pharming Group N.V. is also known for its strong research and development capabilities, which have led to several breakthrough treatments. The company's commitment to innovation is further supported by its smart analysis of market trends and competitive landscape.

Pharming Group N.V. is currently trading at a favorable PEG ratio, indicating that the stock is undervalued compared to its earnings growth. This presents an opportunity for investors to potentially benefit from future price appreciation. Furthermore, when comparing Pharming Group N.V. to its industry peers, it is evident that the company is well-positioned to outperform. Its strong financials and strategic partnerships contribute to its competitive advantage. The stock has shown resilience throughout the past year, with a 52-week range that reflects stability and steady growth. The day range for Pharming Group N.V. indicates active trading, with high volume indicating investor interest and liquidity in the stock. Overall, Pharming Group N.V. presents a compelling investment opportunity with its strong market position and positive growth prospects.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Sijmen de Vries M.B.A., M.D., MBA
Headquarters: Leiden
Employees: 332
Exchange: NASDAQ

Keep an eye on Pharming Group N.V.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Pharming Group N.V.'s (PHAR) price per share?

The current price per share for Pharming Group N.V. (PHAR) is $8.04. The stock has seen a price change of $0.1 recently, indicating a 1.26% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Pharming Group N.V. (PHAR)?

For Pharming Group N.V. (PHAR), the 52-week high is $16.71, which is 107.84% from the current price. The 52-week low is $6.65, the current price is 20.9% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Pharming Group N.V. (PHAR) a growth stock?

Pharming Group N.V. (PHAR) has shown an average price growth of 0.41% over the past three years. It has received a score of 45 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Pharming Group N.V. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Pharming Group N.V. (PHAR) stock price performance year to date (YTD)?

As of the latest data, Pharming Group N.V. (PHAR) has a year-to-date price change of -30.09%. Over the past month, the stock has experienced a price change of 0.75%. Over the last three months, the change has been -1.47%. Over the past six months, the figure is -26.91%.

help

Is Pharming Group N.V. (PHAR) a profitable company?

Pharming Group N.V. (PHAR) has a net income of -$12.01M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 89.72% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -4.21% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $245.32M, with a revenue growth rate of 19.3%, providing insight into the company's sales performance and growth. The gross profit is $220.1M. Operating income is noted at -$5.39M. Furthermore, the EBITDA is -$5.04M.

help

What is the market capitalization of Pharming Group N.V. (PHAR)?

Pharming Group N.V. (PHAR) has a market capitalization of $536.92M. The average daily trading volume is 7.04K, indicating the stock's liquidity and investor engagement.